Aging Research and the Development of Cellular- and Molecular-Based Anti-Aging Therapies
The five-year research roadmap is outlined as follows:
-
Year 1: Aging studies focusing on photoaging, development of photoaging simulation tools, skin co-culture models, and regenerative therapy approaches.
-
Year 2: Design and fabrication of devices, device validation, establishment of co-culture systems, and therapeutic intervention studies.
-
Year 3: Evaluation of the therapeutic efficacy of adipose tissue–derived stem cell secretome and platelet-rich plasma (PRP) on photoaged skin.
-
Year 4: In vivo studies in animal models and combination therapy using secretome and PRP. In addition, molecular docking or in silico analyses of secretome and PRP will be conducted to identify bioactive compounds with preventive potential against photoaging.
-
Year 5: Clinical trials of combination therapy using secretome and PRP in photoaging patients, along with community-based feasibility studies.
Genetic and Epigenetic Studies in Cardiovascular Diseases and Prototype Development
This research focuses on the development of genetic risk panels and differential DNA methylation profiles for disease prevention. The five-year roadmap is as follows:
-
Years 1–2:
a. Development of panels to determine genetic risk factors for hypertension.
b. Identification of epigenetic factors (genetic and environmental, such as diet and pollutants).
c. Research on “Genetic and Epigenetic Factors in Endometriosis.”
d. Research on “Genetic and Epigenetic Factors in Congenital Heart Disease (CHD).” -
Years 3–4: Implementation research of genetic and epigenetic panels in patients with hypertension, endometriosis, and CHD, utilizing machine learning approaches.
-
Year 5: Application of genetic risk factor assessment for hypertension, endometriosis, and CHD, as well as evaluation of environmental factors in the prevention of these diseases.
Development of Cell-Based, Recombinant Protein, RNA, and DNA Therapies for Inherited Metabolic Disorders, The five-year research roadmap is as follows:
-
Year 1: In silico and bioinformatics studies to generate an animal research model, specifically a mouse model of Mucopolysaccharidosis Type II (MPS II), using CRISPR/Cas9 technology.
-
Year 2: Production and amplification of viral vectors carrying the gene encoding iduronidase (IDS).
-
Year 3: Viral vector transduction into mesenchymal stem cells (MSCs) derived from the bone marrow of MPS II mice, followed by MSC culture. Analysis of glycosaminoglycan (GAG) levels and IDS levels in plasma and tissues of MPS II mice, as well as immunohistochemical analysis of GAG distribution in tissues.
-
Year 4: Injection of cultured MSCs into MPS II mice, followed by analysis of GAG and IDS levels in plasma and tissues, and immunohistochemical assessment of GAG in tissues of treated MPS II mice.
-
Year 5: Implementation of MSC-based gene therapy for IDS enzyme production in higher-order mammalian models.
